Search alternatives:
fold decrease » fold increase (Expand Search), fold increased (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 1,141 - 1,160 results of 227,974 for search '(( 5 ((ppm decrease) OR (mean decrease)) ) OR ( a ((fold decrease) OR (a decrease)) ))', query time: 1.64s Refine Results
  1. 1141
    SEM images (at 100x) of (a-1) polished P110 CS and corroded in 15% HCl for 6h (a) in the absence and presence of (b) 5, (c) 6a and (d) 6b.

    SEM images (at 100x) of (a-1) polished P110 CS and corroded in 15% HCl for 6h (a) in the absence and presence of (b) 5, (c) 6a and (d) 6b. by Ghadeer Mubarak (21567569)

    Published 2025
    Save to List
    Saved in:
  2. 1142
    <i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort

    <i>SIRT6</i> Minor Allele Genotype Is Associated with >5-Year Decrease in Lifespan in an Aged Cohort by Mindi J. TenNapel (679433)

    Published 2014
    Save to List
    Saved in:
  3. 1143
    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells.

    BMP type I receptor antagonists decrease Smad 1/5/8 activity in H1299 cells. by Elaine Langenfeld (402034)

    Published 2013
    Save to List
    Saved in:
  4. 1144
    Integrin expression decreased in treated tumors.

    Integrin expression decreased in treated tumors. by Anthony B. Eason (6294305)

    Published 2020
    Save to List
    Saved in:
  5. 1145
    Downregulated proteins in <i>N. gonorrhoeae</i> biofilms listed by functional roles<sup>a</sup>: Biofilm/Planktonic ratios expressed as log<sub>2</sub> values, 2-fold decrease (log<sub>2</sub> values ≤−1.000) measured in at least one Extract, and p-values <0.05.

    Downregulated proteins in <i>N. gonorrhoeae</i> biofilms listed by functional roles<sup>a</sup>: Biofilm/Planktonic ratios expressed as log<sub>2</sub> values, 2-fold decrease (log<sub>2</sub> values ≤−1.000) measured in at least one Extract, and p-values <0.05. by Nancy J. Phillips (160631)

    Published 2012
    Save to List
    Saved in:
  6. 1146
    Correlates of osteogenic differentiation.

    Correlates of osteogenic differentiation. by Fabian Westhauser (5314436)

    Published 2019
    Save to List
    Saved in:
  7. 1147
    Space-time plot of the response to an external perturbation at <i>t</i> = 40, that decreases the stability of <i>NMIIA</i> by a 2-fold increase of its decay rate and at the same time the contractility of <i>NMIIA</i> is switched off (i.e. <i>Pe</i> = 0).

    Space-time plot of the response to an external perturbation at <i>t</i> = 40, that decreases the stability of <i>NMIIA</i> by a 2-fold increase of its decay rate and at the same time the contractility of <i>NMIIA</i> is switched off (i.e.... by Rashmi Priya (159985)

    Published 2017
    Save to List
    Saved in:
  8. 1148
    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis.

    D-4F and L-5F decrease hepatic mRNA level of genes involved in gluconeogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  9. 1149
    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis.

    D-4F and L-5F decrease hepatic mRNA levels of genes involved in lipogenesis. by Kristine C. McGrath (8269155)

    Published 2020
    Save to List
    Saved in:
  10. 1150
    Biochemical Studies and Molecular Dynamic Simulations Reveal the Molecular Basis of Conformational Changes in DNA Methyltransferase‑1

    Biochemical Studies and Molecular Dynamic Simulations Reveal the Molecular Basis of Conformational Changes in DNA Methyltransferase‑1 by Fei Ye (339913)

    Published 2018
    Subjects:
    Save to List
    Saved in:
  11. 1151
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 1152
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 1153
    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments).

    Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 1154
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 1155
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 1156
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 1157
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 1158
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 1159
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 1160
    Long-term anti-nucleocapsid response by baseline patient characteristics.

    Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: